206 related articles for article (PubMed ID: 20842122)
1. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.
Gómez-Benito M; Conchillo A; García MA; Vázquez I; Maicas M; Vicente C; Cristobal I; Marcotegui N; García-Ortí L; Bandrés E; Calasanz MJ; Alonso MM; Odero MD
Br J Cancer; 2010 Oct; 103(8):1292-6. PubMed ID: 20842122
[TBL] [Abstract][Full Text] [Related]
2. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
Watanabe-Okochi N; Yoshimi A; Sato T; Ikeda T; Kumano K; Taoka K; Satoh Y; Shinohara A; Tsuruta T; Masuda A; Yokota H; Yatomi Y; Takahashi K; Kitaura J; Kitamura T; Kurokawa M
Blood; 2013 May; 121(20):4142-55. PubMed ID: 23547050
[TBL] [Abstract][Full Text] [Related]
3. Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.
Kotaki R; Higuchi H; Ogiya D; Katahira Y; Kurosaki N; Yukihira N; Ogata J; Yamamoto H; Mohamad Alba S; Azhim A; Kitajima T; Inoue S; Morishita K; Ono K; Koyama-Nasu R; Kotani A
Int J Hematol; 2017 Dec; 106(6):811-819. PubMed ID: 28831750
[TBL] [Abstract][Full Text] [Related]
4. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
Vázquez I; Maicas M; Marcotegui N; Conchillo A; Guruceaga E; Roman-Gomez J; Calasanz MJ; Agirre X; Prosper F; Odero MD
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):E167-8; author reply E169-70. PubMed ID: 20930122
[No Abstract] [Full Text] [Related]
5. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target.
Yamamoto H; Lu J; Oba S; Kawamata T; Yoshimi A; Kurosaki N; Yokoyama K; Matsushita H; Kurokawa M; Tojo A; Ando K; Morishita K; Katagiri K; Kotani A
Sci Rep; 2016 Jan; 6():19204. PubMed ID: 26754824
[TBL] [Abstract][Full Text] [Related]
6. EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells.
De Weer A; Van der Meulen J; Rondou P; Taghon T; Konrad TA; De Preter K; Mestdagh P; Van Maerken T; Van Roy N; Jeison M; Yaniv I; Cauwelier B; Noens L; Poirel HA; Vandenberghe P; Lambert F; De Paepe A; Sánchez MG; Odero M; Verhasselt B; Philippé J; Vandesompele J; Wieser R; Dastugue N; Van Vlierberghe P; Poppe B; Speleman F
Br J Haematol; 2011 Aug; 154(3):337-48. PubMed ID: 21569010
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
9. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
10. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R
Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866
[TBL] [Abstract][Full Text] [Related]
11. The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia.
Shen C; Chen MT; Zhang XH; Yin XL; Ning HM; Su R; Lin HS; Song L; Wang F; Ma YN; Zhao HL; Yu J; Zhang JW
PLoS Genet; 2016 Sep; 12(9):e1006259. PubMed ID: 27617961
[TBL] [Abstract][Full Text] [Related]
12. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
13. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
[TBL] [Abstract][Full Text] [Related]
16. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
[TBL] [Abstract][Full Text] [Related]
17. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
[TBL] [Abstract][Full Text] [Related]
18. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.
Rommer A; Steinmetz B; Herbst F; Hackl H; Heffeter P; Heilos D; Filipits M; Steinleitner K; Hemmati S; Herbacek I; Schwarzinger I; Hartl K; Rondou P; Glimm H; Karakaya K; Krämer A; Berger W; Wieser R
PLoS One; 2013; 8(2):e56308. PubMed ID: 23457546
[TBL] [Abstract][Full Text] [Related]
19. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
[TBL] [Abstract][Full Text] [Related]
20. Review: Aberrant EVI1 expression in acute myeloid leukaemia.
Hinai AA; Valk PJ
Br J Haematol; 2016 Mar; 172(6):870-8. PubMed ID: 26729571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
